Eli Lilly invested in AbCellera's series B round shortly after agreeing a research and collaboration licensing deal with the drug discovery technology provider.
AbCellera, the Canada-based developer of an antibody drug discovery platform, completed a $105m series B round yesterday that included pharmaceutical firm Eli Lilly.
Healthcare investment firm OrbiMed and venture capital fund DCVC Bio co-led the round, which also featured Viking Global Investors, Founders Fund, University of Minnesota, Presight Capital and private investor Peter Thiel.
Founded in 2012, AbCellera has created a technology platform that uses machine learning and data science to locate antibodies in natural immune systems that could form…
